GlassScriptPhysician profile
Eric William Yuschak
NPI 1437647641
$650.02
in general payments reported to CMS, 2019-2025
9 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.75 · 2022: $34.81 · 2023: $124 · 2024: $284 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $297.90 | 2022-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $176.49 | 2023-2025 | Orthovisc, Monovisc |
| Vertex Pharmaceuticals Incorporated | $62.19 | 2025 | |
| Averitas Pharma INC. | $24.07 | 2024 | Qutenza |
| Merck Sharp & Dohme LLC | $18.98 | 2019 | |
| Abbott Laboratories | $18.77 | 2019 | |
| Bioventus LLC | $18.35 | 2023 | Durolane |
| Electronic Waveform Lab, INC. | $17.35 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.92 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yuschak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.